PaxVax and Valneva will market each other's cholera and typhoid vaccines; Scripps wins $4.5M from Gates Foundation for HIV/AIDS vaccine;

> PaxVax and Valneva have entered into an agreement to market their cholera and typhoid vaccines. PaxVax will market Valneva's Dukoral in Italy, Spain and Portugal, and Valneva will market PaxVax's Vivotif in Canada, Sweden, Norway, Denmark and Finland. Release

> The Scripps Research Institute won two grants from the Bill & Melinda Gates Foundation totaling more than $4.5 million to fund the development of an HIV/AIDS vaccine. Release

> Gaithersburg, MD-based Vaxin announced the enrollment of its first patient into a Phase I trial of HepTcell, its hepatitis B candidate. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.